F-1/A: Empro Group Inc. Files for Nasdaq IPO, Pivots to Skincare Amid Healthcare Revenue Decline

Empro Group Inc., a Malaysian beauty and healthcare company, is seeking to raise approximately $5 million in an initial public offering on the Nasdaq Capital Market, shifting its strategic focus towards high-margin cosmetics and skincare products following a significant decline in its healthcare segment revenue.

Summary

• Empro Group Inc. is pursuing an Initial Public Offering (IPO) of 1,250,000 Ordinary Shares on the Nasdaq Capital Market under the symbol EMPG, with an estimated price range of $4.00 to $4.50 per share.
• The company expects to raise approximately $5 million in gross proceeds from the offering, with net proceeds of about $4.2 million (assuming no over-allotment option exercise).
• Proceeds are earmarked for working capital (45%), market penetration and development (23%), operating expenses (16%), and transaction expenses (16%).
• The company's total revenue increased by 48.37% to $5.48 million in fiscal year 2024, up from $3.70 million in 2023, but significantly down from $10.82 million in 2022.
• Revenue from the healthcare business segment (primarily medical masks) decreased by 35.85% to $2.12 million in 2024, down from $3.32 million in 2023 and $10.55 million in 2022, due to reduced demand post-COVID-19.
• Revenue from the cosmetics and skincare business segment surged by 783.58% to $3.36 million in 2024, up from $0.38 million in 2023 and $0.27 million in 2022, driven by the launch of the SpaceLift skincare product.
• The company reported a net profit of $0.75 million in 2024, a significant improvement from a net loss of $0.32 million in 2023, but lower than the $1.17 million net profit in 2022.
• Gross profit margin improved from 40.1% in 2023 to 61.8% in 2024, primarily due to the strategic shift towards higher-margin cosmetics and skincare products.
• The company's founder, CEO, and Chairman, Yeoh Chee Wei, is expected to beneficially own approximately 64.7% of outstanding Ordinary Shares post-IPO, making Empro Group a 'controlled company' under Nasdaq rules.
• Empro Group operates through its wholly-owned Malaysian subsidiary, EMP Solution Sdn. Bhd., and has established distribution networks with major retailers like Watsons and Sasa, as well as online platforms like Shopee and Lazada.
• The company holds 27 registered trademarks and 5 registered patents for its products, including its Aerofit surgical face masks and triangular eyebrow pencils.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong growth in the high-margin cosmetics and skincare segment, a return to profitability, and ambitious international expansion plans. However, it acknowledges significant risks associated with the declining healthcare segment, reliance on a controlling shareholder, and the inherent uncertainties of new product launches and international market entry. The detailed risk factors temper the overall positive tone, leading to a moderately positive score.

Positives

• Significant revenue growth in the cosmetics and skincare segment, increasing by 783.58% to $3.36 million in 2024, largely due to the successful launch of the SpaceLift skincare product.
• Return to net profitability in 2024 with a net income of $0.75 million, compared to a net loss of $0.32 million in 2023.
• Substantial improvement in gross profit margin from 40.1% in 2023 to 61.8% in 2024, reflecting a successful strategic shift to higher-margin products.
• Strong distribution network including major retailers like Watsons (700+ stores in Malaysia) and Sasa (60+ locations in Malaysia), alongside online platforms.
• Diversification of product offerings with new brands like Premio and Mios eyebrow pencils and the SpaceLift skincare product, reducing reliance on the declining healthcare segment.
• Established brand history spanning nearly two decades with numerous industry awards and accolades, fostering trust and recognition.
• Commitment to product safety and quality, evidenced by rigorous testing and certifications from reputable international organizations like TV-SD, MYCO2, Nelson Labs, and SGS.
• Strategic international expansion plans for SpaceLift into key markets including Hong Kong, Thailand, Singapore, India, Norway, Switzerland, Austria, Romania, China, Denmark, Finland, Sweden, UAE, Slovakia, Japan, the Netherlands, Belgium, and the United States.
• Healthy working capital balance of approximately $1.70 million as of December 31, 2024.
• Improved gearing ratio from 1.69 times in 2023 to 0.93 times in 2024, indicating a stronger financial structure.

Negatives

• Total revenue in 2024 ($5.48 million) remains significantly lower than 2022 revenue ($10.82 million), primarily due to the sharp decline in healthcare product sales.
• The healthcare business segment, which was the primary revenue driver in 2022 and 2023, experienced a substantial decline in sales (35.85% decrease in 2024), indicating a loss of a major revenue stream.
• The company incurred a net loss of $0.32 million in fiscal year 2023.
• High concentration of ownership by Mr. Yeoh Chee Wei (expected 64.7% post-IPO) means he will control the company, potentially leading to interests different from other shareholders and allowing reliance on Nasdaq controlled company exemptions in the future.
• Trade receivables increased significantly to $2,490,539 in 2024 from $596,842 in 2023, with only 16.09% collected as of March 26, 2025, indicating potential cash flow issues or collection challenges.
• Cash and bank balances decreased from $303,384 in 2023 to $128,984 in 2024.
• The company has a limited operating history as a public company and an evolving business strategy, making future performance uncertain.
• Reliance on a limited number of ODM/OEM and packaging supply partners (Jingga Anggun and Mosfac), with related party relationships, poses supply chain and quality control risks.
• Significant increase in operating costs, including marketing and promotional expenses, which may not always be cost-effective or successful.
• The company does not expect to pay dividends in the foreseeable future, meaning investors must rely on share price appreciation for returns.

Risks

• The company operates in highly competitive healthcare and beauty industries, facing large multinational competitors with greater resources.
• Success is dependent on the continued popularity of products and the ability to anticipate and respond to rapidly changing consumer preferences and industry trends.
• There is no assurance that the growth in the cosmetics and skincare segment will sufficiently offset the continued decrease in revenue from the healthcare business segment.
• New product introductions may not be as successful as anticipated, impacting business, financial condition, and results of operations.
• Reliance on third-party e-commerce platforms (Shopee, Lazada, Watsons, Sasa) for online sales exposes the company to risks if services are interrupted or cooperation deteriorates.
• The potential sale of counterfeit products could harm the company's reputation and profitability.
• Inability to accurately forecast consumer demand or adequately manage inventory could lead to obsolescence, write-downs, or lost sales.
• Negative publicity regarding the company, its products, management, or business partners could harm brand and reputation.
• Expansion into international markets exposes the company to significant regulatory, economic, and political risks, and there is no assurance of securing necessary approvals (e.g., USFDA) in a timely manner or at all.
• Economic downturns may adversely affect consumer discretionary spending and demand for beauty products.
• Risks related to data security and privacy, including potential breaches, non-compliance with evolving data protection laws (e.g., Malaysia's PDPA 2010), and flaws in proprietary data analytics algorithms.
• Dependence on information technology systems, with risks of service interruptions, data corruption, and cyber-attacks.
• Failure to obtain and maintain requisite licenses, permits, registrations, and filings, or to obtain additional ones for business expansion, could materially affect operations.
• Acquisition activities and other strategic transactions may present managerial, integration, operational, and financial risks.
• Quarterly operating results may fluctuate due to seasonality and other factors, making results difficult to predict.
• The company is controlled by a single shareholder (Mr. Yeoh), whose interests may differ from other shareholders, and it may elect to rely on controlled company exemptions from Nasdaq corporate governance standards in the future.
• As a foreign private issuer and emerging growth company, the company is subject to reduced reporting requirements, which may provide less protection or information to investors compared to U.S. domestic issuers.
• If classified as a Passive Foreign Investment Company (PFIC), U.S. taxpayers owning Ordinary Shares may face adverse U.S. federal income tax consequences.
• Substantial increased costs will be incurred as a public company, including compliance with Sarbanes-Oxley Act requirements.
• There has been no public market for Ordinary Shares prior to this offering, and the market price may be volatile or decline regardless of operating performance.
• Future sales or perceived potential sales of Ordinary Shares in the public market could cause the price to decline, and existing shareholders may be willing to accept lower sales prices.

Future Outlook

Empro Group plans to expand its product offerings and develop new products, including the Premio and Mios brands and the SpaceLift skincare product. The company intends to expand into new markets and territories within ASEAN, Europe, India, the United States, Canada, UAE, and South Africa within the next five years, aiming to achieve a presence in 30 countries. It will invest in new technologies, including an in-house e-commerce application for B2B and B2C customers, and continue to allocate approximately 5% of forecasted revenues to research and development. The company expects to continue experiencing a reduction in revenue from its healthcare business segment but anticipates growth and increased revenue opportunities from its cosmetic and skincare segment.

Management Comments

• "Our company has steadily and successfully transcended its humble origins in the beauty industry during an operating history that spans nearly two decades."
• "We take immense pride in our surgical face mask products, which we began to market in 2020 during the height of COVID-19 pandemic."
• "Our accomplishments reflect a commitment to providing safe, professional-grade products of uncompromising quality."
• "We take pride in our ability to adapt and respond swiftly to dynamic market needs, positioning our company as a versatile and forward-thinking enterprise."
• "We believe that this multifaceted strategic synergy will remain pivotal in securing sustained success and a prominent industry position as we navigate into the future."
• "We are confident in the prospects of our cosmetic and skincare business segment, as these areas show strong potential for growth."
• "We view the post-pandemic era as an exciting chapter, where the resilience of our brand and the loyalty of our customers will play pivotal roles in our continued success."
• "We believe that our current cash and cash flows provided by operating activities will be sufficient to meet our working capital needs in the next 12 months from the date of this prospectus."
• "We believe that our new SpaceLift product provides a natural and safe anti-sagging and anti-aging solution for those who seek a safe and effective skin lifting product."
• "We believe that our presence at these events underscores our commitment to innovation and excellence in the beauty industry."
• "We believe that our SpaceLift product is well positioned to compete against the facial skincare product offerings of these competitors due to the results that it delivers and the fact that it is formulated to provide a broader array of benefits, including pore minimization, UV protection and anti-inflammation."
• "We believe that the reliability of our brands and our dedication to innovation set us apart."
• "We believe that this multifaceted approach not only safeguards our current ventures but also positions us for sustained success as we navigate the global market."

Industry Context

Empro Group operates in the growing global beauty and personal care market, projected to reach $580 billion by 2027, and the Personal Protective Equipment (PPE) market, expected to reach $113 billion by 2029. The company is strategically pivoting from its declining healthcare segment (medical masks, post-COVID-19) to the high-growth skincare and cosmetics segments, aligning with broader industry trends of increasing consumer discretionary spending in ASEAN, tourism recovery in Malaysia, and a tech-savvy, beauty-conscious youth population. The industry is highly competitive and fragmented, with consumers open to trying new brands, creating opportunities for innovative players like Empro. The company's omni-channel approach (online and physical stores) reflects the evolving retail landscape where both channels remain crucial.

Comparison to Industry Standards

• In the cosmetics market, particularly for eyebrow pencils, Empro's primary competitors are luxury Japanese brand Shu Uemura (controlled by L'Oréal Group) and Bobbi Brown (owned by The Estée Lauder Companies).
• For its SpaceLift skincare product, Empro competes with globally recognized brands such as Clarins (plant-based skincare), SK-II (Japanese luxury skincare, typically higher price point), Kiehl's (American cosmetics, controlled by L'Oréal Group), Hada Labo (Japanese skincare), and Eucerin (Beiersdorf AG).
• Empro believes SpaceLift is well-positioned against these competitors due to its delivered results and broader benefits (pore minimization, UV protection, anti-inflammation).
• In the medical face mask market, Empro's primary competitors are Malaysian brands Medicos and Neutrovis.
• The company's gross profit margin of 61.8% in 2024 for its overall business, driven by the high-margin cosmetics and skincare segment (72.5% gross margin), suggests strong product profitability compared to the lower margins typically seen in commoditized healthcare products (44.8% gross margin in 2024).
• The company's strategic shift towards higher-margin products aligns with a common industry trend for beauty companies to improve profitability and financial resilience.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to, and is not aware of any threat of, any legal or administrative proceedings that are likely to have any material and adverse effect on its business, financial condition, cash flow, or results of operations.
• The company may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of business, including actions with respect to intellectual property infringement, violation of third-party licenses or other rights, breach of contract, and labor and employment claims.

Related Party Transactions

• As of December 31, 2024, EMP Solution had a balance due to Mr. Yeoh (CEO and director) of $237,032, arising from advances and payments made on behalf of EMP Solution, which are non-interest bearing and due on demand.
• EMP Solution has an Exclusive Sole Distribution Agreement with Jingga Anggun Sdn Bhd (sole director is Mr. Yeoh's son; Mr. Chin, COO of Empro Group, is COO of Jingga Anggun) for medical facemasks. Payments to Jingga Anggun were $1,282,186 in 2024 and $1,526,651 in 2023. Amounts owed to Jingga Anggun were $468,050 in 2024 and $437,682 in 2023.
• EMP Solution has an arrangement with Mosfac Sdn Bhd (Mr. Yeoh is a 50% shareholder and director) for the supply of triangular eyebrow pencils and related products. Outstanding receivables from Mosfac were $10,725 in 2024 and $325,522 in 2023. Outstanding payables to Mosfac were $7,209 in 2024 and $0 in 2023.
• As of December 31, 2023, EMP Solution had outstanding receivables of $29,956 from Mimo Motor Sdn Bhd (Mr. Yeoh is sole shareholder and director), which were reduced to $0 by December 31, 2024.
• As of December 31, 2024, EMP Solution had outstanding payables of $23,240 to Brand Multi Plus Sdn Bhd (sole director and shareholder is Mr. Yeoh's son), arising from property, plant, and equipment purchases.

Stakeholder Impact

• **Shareholders**: New investors will experience immediate and substantial dilution in net tangible book value per share ($3.53 per share at midpoint IPO price). Existing shareholders will see an increase in net tangible book value. The controlling ownership by Mr. Yeoh may limit the influence of other shareholders. No dividends are expected in the foreseeable future, relying on price appreciation for returns.
• **Employees**: The company plans to hire additional personnel and expects increased operating costs, including salaries, indicating potential growth in employment opportunities. Employee benefits and statutory contributions are in compliance with Malaysian law.
• **Customers**: The company's strategic pivot to cosmetics and skincare, new product launches (SpaceLift, Premio, Mios), and expansion into new markets aim to offer a broader range of products and enhance customer accessibility and satisfaction. Product safety and quality are emphasized through rigorous testing and certifications.
• **Suppliers/Partners**: The company relies on a limited number of ODM/OEM and packaging supply partners, particularly Jingga Anggun and Mosfac, with whom it has long-term agreements. Strong relationships with distribution partners like Watsons and Sasa are crucial for market reach and sales.
• **Creditors**: The company's ability to meet financial obligations is supported by internally generated cash flows and committed credit lines. The gearing ratio improved from 1.69 in 2023 to 0.93 in 2024, indicating reduced financial leverage.

Next Steps

• Complete the Initial Public Offering and list Ordinary Shares on the Nasdaq Capital Market under the symbol EMPG.
• Allocate net proceeds from the IPO for working capital, market penetration and development (geographical expansion and marketing initiatives), operating expenses, and transaction expenses.
• Continue expanding product offerings and developing new products, including the commercial launch of the Premio brand eyebrow pencil in Q2 2025.
• Expand into new international markets for SpaceLift (China, Denmark, Finland, Sweden, UAE, Slovakia, Japan, the Netherlands, Belgium, and the United States) and medical facemasks (India, Europe, and the United States) over the next 12 months.
• Secure necessary regulatory approvals (e.g., USFDA) for products in new target markets.
• Invest in new technologies, including the development of an in-house e-commerce application (CRM for B2B and B2C).
• Continue to invest approximately 5% of forecasted revenues in research and development activities.
• Monitor and manage trade receivables to improve collection rates and cash flow.
• Establish a compensation committee and nominating and corporate governance committee under the board of directors, with independent directors serving on each.

Key Dates

Recommendation

Keywords

Beauty Products, Healthcare Products, Cosmetics, Skincare, Medical Face Masks, IPO, Nasdaq, Malaysia, ASEAN, International Expansion, E-commerce, Distribution Network, SpaceLift, EMPRO, ODM, OEM, Controlled Company, SEC Filing, F-1/A